In a series of preclinical experiments, we have shown that anti-EGFR targeted immunoliposomes may enhance drug efficacy in vivo14 and, perhaps even more importantly, overcome multidrug-resistance in EGFR-overexpressing cancer cells, including in the human breast cancer cell line MDA-MB-23115). Here, EGFR is linked to breast cancer.